Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia

被引：0

作者：

Jie Sun ^{[1
]}

Juan Hu ^{[1
]}

Yan Huang ^{[1
]}

Shuang-Wei Ying ^{[1
]}

Xiao-Yan Han ^{[1
]}

Yan-Long Zheng ^{[1
]}

He Huang ^{[1
]}

机构：

[1] Bone Marrow Transplantation Centre,The First Affiliated Hospital of Zhejiang University

来源：

中华医学杂志英文版 | 2016年 / 129卷 / 20期

基金：

中国国家自然科学基金;

关键词：

D O I：

暂无

中图分类号：

R581.4 [甲状腺炎]; R733.7 [白血病];

学科分类号：

1002 ; 100201 ; 100214 ;

摘要：

To the Editor:Sorafenib is a novel,orally available inhibitor of multiple kinases.It has been used in relapsed and refractory FMS-like tyrosine kinase（FLT） -3-positive acute myeloid leukemia（AML） in recent years with favorable outcomes.Thyroiditis and hypothyroidism as side effects have been reported in treatment on renal cell cancer.;Here,we report a case of FLT3-internal tandem duplication（ITD） -positive AML,who developed subacute thyroiditis during treatment with sorafenib.

引用

页码：2512 / 2513

页数：2

共 50 条

[1] Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia
Sun, Jie
Hu, Juan
Huang, Yan
Ying, Shuang-Wei
Han, Xiao-Yan
Zheng, Yan-Long
Huang, He
CHINESE MEDICAL JOURNAL, 2016, 129 (20) : 2512 - 2513
[2] Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports
Osone, Shinya
Imamura, Toshihiko
Kanayama, Takuyo
Tsuma, Yusuke
Kawashima-Goto, Sachiko
Nakatani, Takuya
Sugimoto, Atsuya
Takai, Akari
Miyachi, Mitsuru
Tamura, Shinichi
Ishida, Hiroyuki
Hosoi, Hajime
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (04) : E199 - E202
[3] Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia
Gill, Harinder
Man, Cheuk-Him
Ip, Alvin H. W.
Choi, William W. L.
Chow, Howard C. H.
Kwong, Yok-Lam
Leung, Anskar Y. H.
HAEMATOLOGICA, 2015, 100 (07) : E250 - E253
[4] Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3
Zhang, Chunxiao
Lam, Stephen S. Y.
Leung, Garret M. K.
Tsui, Sze-Pui
Yang, Ning
Ng, Nelson K. L.
Ip, Ho-Wan
Au, Chun-Hang
Chan, Tsun-Leung
Ma, Edmond S. K.
Yip, Sze-Fai
Lee, Harold K. K.
Lau, June S. M.
Luk, Tsan-Hei
Li, Wa
Kwong, Yok-Lam
Leung, Anskar Y. H.
CANCER, 2020, 126 (02) : 344 - 353
[5] Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells
Zhang, Yudong
Yuan, Lingli
SCIENTIFIC REPORTS, 2021, 11 (01)
[6] Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells
Yudong Zhang
Lingli Yuan
Scientific Reports, 11
[7] FMS-like tyrosine kinase 3 internal tandem duplication mutation in patients with acute myeloid leukemia in Kurdistan region/Iraq
Rasool, Sarween Sherzad
Mohammad, Nawsherwan Sadiq
Hamza, Hiwa Hassan
Alnuaimy, Sarah Laith
IRAQI JOURNAL OF HEMATOLOGY, 2023, 12 (02) : 159 - 163
[8] Raman identification of single cell component and FMS-like tyrosine kinase 3-internal tandem duplications subtype for clinical acute myeloid leukemia
Wang, Yimeng
Wu, Yihui
Chi, Mingbo
Li, Mingxin
Gao, Sujun
Su, Long
Han, Wei
JOURNAL OF RAMAN SPECTROSCOPY, 2023, 54 (06) : 596 - 607
[9] Acute myeloid leukemia with internal tandem duplication of Fms-like tyrosine kinase 3 gene. A promising selective inhibitor: quizartinib
Lauren, Barette
HEMATOLOGIE, 2023, 29 (04): : 225 - 226
[10] FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
von Bubnoff, Nikolas
Engh, Richard A.
Aberg, Espen
Sanger, Jana
Peschel, Christian
Duyster, Justus
CANCER RESEARCH, 2009, 69 (07) : 3032 - 3041

← 1 2 3 4 5 →